2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Effects of Sex, Age, and Apolipoprotein E Genotype on Brain Ceramides and Sphingosine-1-Phosphate in Alzheimer’s Disease and Control Mice

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Apolipoprotein ε4 ( APOE)4 is a strong risk factor for the development of Alzheimer’s disease (AD) and aberrant sphingolipid levels have been implicated in AD. We tested the hypothesis that the APOE4 genotype affects brain sphingolipid levels in AD. Seven ceramides and sphingosine-1-phosphate (S1P) were quantified by LC-MSMS in hippocampus, cortex, cerebellum, and plasma of <3 months and >5 months old human APOE3 and APOE4-targeted replacement mice with or without the familial AD (FAD) background of both sexes (145 animals). APOE4 mice had higher Cer(d18:1/24:0) levels in the cortex (1.7-fold, p = 0.002) than APOE3 mice. Mice with AD background showed higher levels of Cer(d18:1/24:1) in the cortex than mice without (1.4-fold, p = 0.003). S1P levels were higher in all three brain regions of older mice than of young mice (1.7-1.8-fold, all p ≤ 0.001). In female mice, S1P levels in hippocampus ( r = −0.54 [−0.70, −0.35], p < 0.001) and in cortex correlated with those in plasma ( r = −0.53 [−0.71, −0.32], p < 0.001). Ceramide levels were lower in the hippocampus (3.7–10.7-fold, all p < 0.001), but higher in the cortex (2.3–12.8-fold, p < 0.001) of female than male mice. In cerebellum and plasma, sex effects on individual ceramides depended on acyl chain length (9.5-fold lower to 11.5-fold higher, p ≤ 0.001). In conclusion, sex is a stronger determinant of brain ceramide levels in mice than APOE genotype, AD background, or age. Whether these differences impact AD neuropathology in men and women remains to be investigated.

          Related collections

          Most cited references91

          • Record: found
          • Abstract: not found
          • Article: not found

          Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

            The apolipoprotein E type 4 allele (APOE-epsilon 4) is genetically associated with the common late onset familial and sporadic forms of Alzheimer's disease (AD). Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE-epsilon 4 alleles in 42 families with late onset AD. Thus APOE-epsilon 4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE-epsilon 4 was virtually sufficient to cause AD by age 80.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The global prevalence of dementia: a systematic review and metaanalysis.

              The evidence base on the prevalence of dementia is expanding rapidly, particularly in countries with low and middle incomes. A reappraisal of global prevalence and numbers is due, given the significant implications for social and public policy and planning. In this study we provide a systematic review of the global literature on the prevalence of dementia (1980-2009) and metaanalysis to estimate the prevalence and numbers of those affected, aged ≥60 years in 21 Global Burden of Disease regions. Age-standardized prevalence for those aged ≥60 years varied in a narrow band, 5%-7% in most world regions, with a higher prevalence in Latin America (8.5%), and a distinctively lower prevalence in the four sub-Saharan African regions (2%-4%). It was estimated that 35.6 million people lived with dementia worldwide in 2010, with numbers expected to almost double every 20 years, to 65.7 million in 2030 and 115.4 million in 2050. In 2010, 58% of all people with dementia lived in countries with low or middle incomes, with this proportion anticipated to rise to 63% in 2030 and 71% in 2050. The detailed estimates in this study constitute the best current basis for policymaking, planning, and allocation of health and welfare resources in dementia care. The age-specific prevalence of dementia varies little between world regions, and may converge further. Future projections of numbers of people with dementia may be modified substantially by preventive interventions (lowering incidence), improvements in treatment and care (prolonging survival), and disease-modifying interventions (preventing or slowing progression). All countries need to commission nationally representative surveys that are repeated regularly to monitor trends. Copyright © 2013 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Aging Neurosci
                Front Aging Neurosci
                Front. Aging Neurosci.
                Frontiers in Aging Neuroscience
                Frontiers Media S.A.
                1663-4365
                27 October 2021
                2021
                : 13
                : 765252
                Affiliations
                [1] 1Department of Internal Medicine, Erasmus University Medical Center , Rotterdam, Netherlands
                [2] 2Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University , Maastricht, Netherlands
                [3] 3Department of Molecular Cell Biology and Immunology, Amsterdam Neuroscience, VU Medical Center, Amsterdam UMC , Amsterdam, Netherlands
                [4] 4Department of Neurology, University Hospital Bonn, Venusberg Campus , Bonn, Germany
                [5] 5Department of Clinical Chemistry, Erasmus University Medical Center , Rotterdam, Netherlands
                [6] 6Leiden Institute of Chemistry, Leiden University , Leiden, Netherlands
                Author notes

                Edited by: Kristine Freude, University of Copenhagen, Denmark

                Reviewed by: Malin Wennström, Lund University, Sweden; Robert Piotr Strosznajder, Mossakowski Medical Research Centre, Polish Academy of Sciences (PAN), Poland

                *Correspondence: Pilar Martinez-Martinez, p.martinez@ 123456maastrichtuniversity.nl

                These authors share first authorship

                These authors share senior authorship

                Article
                10.3389/fnagi.2021.765252
                8579780
                34776936
                1e695a88-414e-4c9c-a696-61ccca0642a3
                Copyright © 2021 den Hoedt, Crivelli, Leijten, Losen, Stevens, Mané-Damas, de Vries, Walter, Mirzaian, Sijbrands, Aerts, Verhoeven, Martinez-Martinez and Mulder.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 26 August 2021
                : 29 September 2021
                Page count
                Figures: 3, Tables: 2, Equations: 0, References: 91, Pages: 11, Words: 10381
                Categories
                Neuroscience
                Original Research

                Neurosciences
                ceramide,s1p,apolipoprotein e4,alzheimer’s disease,aging,sex differences
                Neurosciences
                ceramide, s1p, apolipoprotein e4, alzheimer’s disease, aging, sex differences

                Comments

                Comment on this article